OmniAb Future Growth
Future criteria checks 2/6
OmniAb is forecast to grow earnings and revenue by 51.3% and 26.5% per annum respectively while EPS is expected to grow by 53.8% per annum.
Key information
51.3%
Earnings growth rate
53.75%
EPS growth rate
| Life Sciences earnings growth | 17.5% |
| Revenue growth rate | 26.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 08 May 2026 |
Recent future growth updates
Analysis Article • Aug 09
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
NasdaqGM:OABI 1 Year Share Price vs Fair Value Explore OmniAb's Fair Values from the Community and select yours...Analysis Article • May 11
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
It's shaping up to be a tough period for OmniAb, Inc. ( NASDAQ:OABI ), which a week ago released some disappointing...Recent updates
Narrative Update • Apr 27
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.Narrative Update • Apr 08
OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).Narrative Update • Mar 25
OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.Narrative Update • Mar 08
OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.Narrative Update • Feb 21
OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.Narrative Update • Feb 06
OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.Narrative Update • Jan 22
OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.Narrative Update • Jan 08
OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).Narrative Update • Dec 16
OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.Narrative Update • Dec 02
OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.Narrative Update • Nov 18
OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.Analysis Article • Oct 10
OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Analysis Article • Aug 09
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
NasdaqGM:OABI 1 Year Share Price vs Fair Value Explore OmniAb's Fair Values from the Community and select yours...Analysis Article • Jul 09
Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
OmniAb, Inc. ( NASDAQ:OABI ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Seeking Alpha • May 12
OmniAb: Too Much Risk, Not Enough Reward
Summary OmniAb's innovative business model relies on licensing transgenic animals for drug discovery, but financial success hinges on partner drug approvals, which have been slow. Nearly three quarters of the late-stage pipeline's value is concentrated in just a single drug, IMVT-1402. OmniAb faces a cash burn issue, with operating expenses likely to outpace royalties for years before late-stage candidates meaningfully contribute. The FDA's shift away from animal trials threatens OmniAb's core business model, making the stock expensive and risky; I rate it a Sell. Read the full article on Seeking AlphaAnalysis Article • May 11
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
It's shaping up to be a tough period for OmniAb, Inc. ( NASDAQ:OABI ), which a week ago released some disappointing...Analysis Article • Apr 20
OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, OmniAb, Inc. ( NASDAQ:OABI ) shares are down a considerable 29% in the last...
New Narrative • Mar 29
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.Analysis Article • Nov 15
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Analysis Article • Sep 14
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Jul 15
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Key Insights OmniAb's estimated fair value is US$7.87 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysis Article • May 12
The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
OmniAb, Inc. ( NASDAQ:OABI ) just released its latest quarterly report and things are not looking great. It was not a...Analysis Article • Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Today is shaping up negative for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a substantial...Analysis Article • Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Analysis Article • Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Key Insights The projected fair value for OmniAb is US$8.52 based on 2 Stage Free Cash Flow to Equity OmniAb's US$6.22...Analysis Article • Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 7.6x may look like a poor investment opportunity when...Analysis Article • Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Analysis Article • May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on OmniAb, Inc. ( NASDAQ:OABI ) - they aren't optimistic, having just made a...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 60 | -20 | -11 | N/A | 5 |
| 12/31/2027 | 46 | -37 | -41 | N/A | 6 |
| 12/31/2026 | 30 | -54 | -41 | N/A | 7 |
| 3/31/2026 | 29 | -54 | -26 | -25 | N/A |
| 12/31/2025 | 19 | -65 | -37 | -36 | N/A |
| 9/30/2025 | 21 | -64 | -35 | -35 | N/A |
| 6/30/2025 | 23 | -64 | -32 | -31 | N/A |
| 3/31/2025 | 27 | -61 | -40 | -39 | N/A |
| 12/31/2024 | 26 | -62 | -42 | -40 | N/A |
| 9/30/2024 | 20 | -63 | -47 | -45 | N/A |
| 6/30/2024 | 22 | -62 | -47 | -45 | N/A |
| 3/31/2024 | 21 | -63 | -45 | -42 | N/A |
| 12/31/2023 | 34 | -51 | 1 | 2 | N/A |
| 9/30/2023 | 65 | -30 | -2 | 4 | N/A |
| 6/30/2023 | 66 | -27 | -4 | 6 | N/A |
| 3/31/2023 | 66 | -22 | -1 | 12 | N/A |
| 12/31/2022 | 59 | -22 | -21 | -4 | N/A |
| 9/30/2022 | 39 | -32 | -15 | -1 | N/A |
| 6/30/2022 | 38 | -28 | -12 | -1 | N/A |
| 3/31/2022 | 38 | -25 | -3 | 4 | N/A |
| 12/31/2021 | 35 | -27 | -10 | -6 | N/A |
| 9/30/2021 | 33 | -24 | -2 | 0 | N/A |
| 12/31/2020 | 23 | -18 | 4 | 4 | N/A |
| 12/31/2019 | 18 | -14 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OABI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OABI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OABI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OABI's revenue (26.5% per year) is forecast to grow faster than the US market (11.6% per year).
High Growth Revenue: OABI's revenue (26.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OABI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 20:12 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OmniAb, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |